Kymera completes enrollment in KT-621 atopic dermatitis trial

Markets Investing.com By Investing.com 25 Jun 2026 11:18 1 min read

Kymera completes enrollment in KT-621 atopic dermatitis trial

Kymera completes enrollment in KT-621 atopic dermatitis trial

Kymera completes enrollment in KT-621 atopic dermatitis trial

Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.